Navigation Links
Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
Date:8/25/2013

ues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen's business.  Unless otherwise noted, Amgen is providing this information as of August 25, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects.  Risks and uncertainties include whether the proposed transaction described in this press release can be completed in a timely manner, and whether the anticipated benefits of the proposed transaction can be achieved.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for Amgen to complete c
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... , , , Funding and ... NEW YORK, Dec. 14 The Microbicides Development Programme announced ... conducted among almost 9,400 women in four African countries, found ... of HIV infection. , Reacting to today,s announcement, AVAC executive ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced that Steve ... the 2009 DB-Biotech Boston Confab on December 15, 2009 at ... audio webcast of the presentation, investors and other interested parties ... corporate website at www.intermune.com. The company recommends logging on ...
Cached Medicine Technology:AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 2AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 3
(Date:7/13/2014)... Ticket Down is a reliable source ... For the fifth straight year (and second under the current ... American stadiums this summer. The tournament features eight club teams ... teams are split into two groups of four and upon ... will compete to become champion. One team that has had ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic ... eosinophillic esophagitis (EoE), opening up potential new therapeutic ... , EoE is a chronic inflammatory disorder ... allergic hypersensitivity to certain foods and an over-accumulation ... eosinophils (part of the body,s immune system). EoE ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from ... . Additionally, the company’s chief executive officer has announced a ... caskets are offered at discounted prices, from 15 to 26 ... caskets are in huge demand in the current market. We ... We have a lot of high quality products for sale. ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized ... as wells as to maintain soil quality. The application ... become a dominant revenue generator for manufacturers in future. ... resource costs has led to the adoption of micro ... further caused massive demand for micro irrigation systems, as ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
Breaking Medicine News(10 mins):Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... The chances of infection are boosted 50-fold to 100,000-fold, study ... discovery that perplexes HIV experts, an international team reports that ... of the virus to do its damage. , According to ... , the fibers capture the virus and then ferry it ...
... this dependence could stop disease before it starts , ... growth factors contributes to the development of cancers caused ... a normally silent gene, scientists say. , The team ... addiction might help prevent cancer growth. , They ...
... eye also detects light for a number of non-visual phenomena. ... sleep/wake cycle, which is synchronized by the effects of light ... a study published online on December 13th in Current Biology, ... to light remain intact, suggesting that visual and non-visual responses ...
... Dec. 13 A letter recently sent to,presidential ... according to groups representing full-service community hospitals.,Those groups, ... Hospital,Association (AHA), sent their own letter to the ... impact of limited-service facilities, which,drive up the nation,s ...
... to common ... antibiotic treatment, BERKELEY SPRINGS, W.Va., ... sprays provide little,to no relief of symptoms associated with sinus infections. ... they,took antibiotics, steroids, or placebos., One such study appears in ...
... Extend Product Offering to Healthcare Customers, DALLAS, ... leading provider of electronic transaction services to the,Healthcare ... an agreement,to acquire substantially all the assets of ... is subject to due diligence and is structured,as ...
Cached Medicine News:Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Cell 'Addiction' to Growth Factors May Help Spur Cancers 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 3Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 2Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 3Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 4Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 5Health News:31 Million Americans Suffer From Sinus Infections 2Health News:Claimsnet to Acquire Acceptius 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Medicine Products: